BioSpace News Archive

Business

VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters

This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec (VB-111), if approved.

October 23, 2017

·

6 min read

Biotech Bay

Soleno Therapeutics Regains Compliance With NASDAQ Listing Requirements

Soleno is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market and NASDAQ considers the matter closed.

October 23, 2017

·

2 min read

Business

Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors

Dr. Diaz brings to the company his world-renowned expertise in cancer genetics and a precision medicine approach to immuno-oncology.

October 23, 2017

·

4 min read

Drug Development

Achillion Announces Presentation of Data From OMEGA-1 Phase IIb Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting

98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6.

October 23, 2017

·

4 min read

Bio NC

RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering RHB-104

RHB-104 is a proprietary, orally-administered, potentially ground-breaking, antibiotic combination therapy with potent intracellular, antimycobacterial and anti-inflammatory properties.

October 23, 2017

·

9 min read

Drug Development

Ergomed’s First-in-Class Haemostat, Peprostat, Reports Positive Top-Line Results and Meets Key Endpoints in Phase II Study

Ergomed plc announces positive top-line results from its Phase II clinical trial of PeproStat, the Company’s potential first-in-class coagulant, or ‘haemostat’, for intraoperative surgical bleeding.

October 23, 2017

·

6 min read

Drug Development

Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting

Results demonstrate that mgl-3196 provides metabolic, anti-inflammatory and anti-fibrotic benefits in a long-term, high fat diet, mouse NASH model.

October 23, 2017

·

3 min read

Business

Collaborative Clinical Study Aims to Advance Treatment of Kidney and Prostate Cancer with 3D Printing

Stratasys announced a new clinical study is being conducted with the New York University (NYU) School of Medicine – aimed at advancing diagnosis and treatment of complex kidney and prostate tumors through imaging and 3D printing.

October 23, 2017

·

5 min read

Novo Nordisk: Share Repurchase Programme

Under the programme initiated 9 August 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 3.9 billion in the period from 9 August 2017 to 30 October 2017.

October 23, 2017

·

1 min read

Drug Development

TiGenix Granted Orphan Drug Designation From the U.S. FDA for Cx601

TiGenix NV announces that the FDA has granted orphan drug designation (ODD) to Cx601 for the treatment of patients with fistulizing Crohn´s disease.

October 23, 2017

·

4 min read